These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: a case-control study. Schepis F; Vukotic R; Berzigotti A; Carrión JA; Forns X; Abraldes JG; García-Valdecasas JC; Navasa M; García-Pagán JC; Bosch J Liver Transpl; 2013 Apr; 19(4):450-6. PubMed ID: 23408436 [TBL] [Abstract][Full Text] [Related]
29. [Evaluation of propranolol response by catheterization and Doppler ultrasonography in patients with cirrhosis]. Castaño G; Viudez P; Carlevaro O; Ocampo C; Zandalazini H; Riccitelli M; Sookoian S; Frider B Acta Gastroenterol Latinoam; 1998; 28(4):291-7. PubMed ID: 10347683 [TBL] [Abstract][Full Text] [Related]
30. Portal pressure response to propranolol in portal hypertension. Ozsoylu S; Koçak N; Yüce A; Ozbag E J Hepatol; 1992 May; 15(1-2):270-1. PubMed ID: 1506652 [No Abstract] [Full Text] [Related]
31. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Bañares R; Moitinho E; Piqueras B; Casado M; García-Pagán JC; de Diego A; Bosch J Hepatology; 1999 Jul; 30(1):79-83. PubMed ID: 10385642 [TBL] [Abstract][Full Text] [Related]
32. Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity. Baik SK; Park DH; Kim MY; Choi YJ; Kim HS; Lee DK; Kwon SO; Kim YJ; Park JW; Chang SJ J Gastroenterol; 2003; 38(12):1150-4. PubMed ID: 14714252 [TBL] [Abstract][Full Text] [Related]
33. Portal and systemic effects of selective infusion of vasopressin into the superior mesenteric artery in cirrhotic patients. Millette B; Huet PM; Lavoie P; Viallet A Gastroenterology; 1975 Jul; 69(1):6-12. PubMed ID: 1150036 [TBL] [Abstract][Full Text] [Related]
34. [Pharmacological therapy of portal hypertension--focused on Korean data]. Baik SK Korean J Gastroenterol; 2005 Jun; 45(6):381-6. PubMed ID: 15973071 [TBL] [Abstract][Full Text] [Related]
35. Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension. Kim JH; Kim JM; Cho YZ; Na JH; Kim HS; Kim HA; Kang HW; Baik SK; Kwon SO; Cha SH; Kim YJ; Kim MY Clin Mol Hepatol; 2014 Dec; 20(4):376-83. PubMed ID: 25548744 [TBL] [Abstract][Full Text] [Related]
36. Portal pressure response to losartan compared with propranolol in patients with cirrhosis. De BK; Bandyopadhyay K; Das TK; Das D; Biswas PK; Majumdar D; Mandal SK; Ray S; Dasgupta S Am J Gastroenterol; 2003 Jun; 98(6):1371-6. PubMed ID: 12818283 [TBL] [Abstract][Full Text] [Related]
37. [Propranolol and 5-isosorbide mononitrate in patients with cirrhosis: systemic and portal hemodynamic events]. Castaño G; Viudez P; Sookoian S; Carlevaro O; Riccitelli M; Frider B Gastroenterol Hepatol; 2000; 23(6):275-81. PubMed ID: 15324622 [TBL] [Abstract][Full Text] [Related]
39. [Propranolol in children and adolescents with portal hypertension: its dosage and the clinical, cardiovascular and biochemical effects]. de Kolster CC; Rapa de Higuera M; Carvajal A; Castro J; Callegari C; Kolster J G E N; 1992; 46(3):199-207. PubMed ID: 1340825 [TBL] [Abstract][Full Text] [Related]